OBJECTIVE: Success after islet transplantation can be defined in terms of insulin independence, C-peptide secretion, or glycemic control. These measures are interdependent and all need to be considered in evaluating beta-cell function after islet transplantation. For the current study, a composite beta-score was developed that provides an integrated measure of beta-cell function success after islet transplantation. RESEARCH DESIGN AND METHODS: The proposed scoring system gave 2 points each for normal fasting glucose, HbA(1c), stimulated C-peptide, and absence of insulin or oral hypoglycemic agent use. No points were awarded if the fasting glucose was in the diabetic range, the HbA(1c) was >6.9%, C-peptide secretion was absent on stimulation, or daily insulin use was in excess of 0.24 units/kg. One point was given for intermediate values. The score ranged from 0 to 8 and was correlated with the glucose value 90 min after a standard mixed meal challenge (n = 218) in 57 subjects before and after islet transplantation. The score was also used to follow subjects for up to 5 years after islet transplantation. RESULTS: The beta-score correlated well with the plasma glucose level 90 min after a mixed meal challenge (r = -0.849, P < 0.001). On follow-up, the beta-score rose after the first transplant and was maintained up to 5 years, demonstrating continuing function of the transplanted beta-cells. CONCLUSIONS: The beta-score provides a simple clinical scoring system that encompasses glycemic control, diabetes therapy, and endogenous insulin secretion that correlates well with physiological measures of beta-cell function. On this basis, it is suitable as an overall measure of beta-cell transplant function. The beta-score gives an integrated measure of beta-cell function as a continuum that may be more useful than simply assessing the presence or absence of insulin independence.
OBJECTIVE: Success after islet transplantation can be defined in terms of insulin independence, C-peptide secretion, or glycemic control. These measures are interdependent and all need to be considered in evaluating beta-cell function after islet transplantation. For the current study, a composite beta-score was developed that provides an integrated measure of beta-cell function success after islet transplantation. RESEARCH DESIGN AND METHODS: The proposed scoring system gave 2 points each for normal fasting glucose, HbA(1c), stimulated C-peptide, and absence of insulin or oral hypoglycemic agent use. No points were awarded if the fasting glucose was in the diabetic range, the HbA(1c) was >6.9%, C-peptide secretion was absent on stimulation, or daily insulin use was in excess of 0.24 units/kg. One point was given for intermediate values. The score ranged from 0 to 8 and was correlated with the glucose value 90 min after a standard mixed meal challenge (n = 218) in 57 subjects before and after islet transplantation. The score was also used to follow subjects for up to 5 years after islet transplantation. RESULTS: The beta-score correlated well with the plasma glucose level 90 min after a mixed meal challenge (r = -0.849, P < 0.001). On follow-up, the beta-score rose after the first transplant and was maintained up to 5 years, demonstrating continuing function of the transplanted beta-cells. CONCLUSIONS: The beta-score provides a simple clinical scoring system that encompasses glycemic control, diabetes therapy, and endogenous insulin secretion that correlates well with physiological measures of beta-cell function. On this basis, it is suitable as an overall measure of beta-cell transplant function. The beta-score gives an integrated measure of beta-cell function as a continuum that may be more useful than simply assessing the presence or absence of insulin independence.
Authors: D Hirsch; J Odorico; J S Danobeitia; R Alejandro; M R Rickels; M Hanson; N Radke; D Baidal; D Hullett; A Naji; C Ricordi; D Kaufman; L Fernandez Journal: Am J Transplant Date: 2012-02-02 Impact factor: 8.086
Authors: A N Balamurugan; Gopalakrishnan Loganathan; Melena D Bellin; Joshua J Wilhelm; James Harmon; Takayuki Anazawa; Sajjad M Soltani; David M Radosevich; Takeshi Yuasa; Mukesh Tiwari; Klearchos K Papas; Robert McCarthy; David E R Sutherland; Bernhard J Hering Journal: Transplantation Date: 2012-04-15 Impact factor: 4.939
Authors: Wilson Km Wong; Guozhi Jiang; Anja E Sørensen; Yi Vee Chew; Cody Lee-Maynard; David Liuwantara; Lindy Williams; Philip J O'Connell; Louise T Dalgaard; Ronald C Ma; Wayne J Hawthorne; Mugdha V Joglekar; Anandwardhan A Hardikar Journal: JCI Insight Date: 2019-07-30
Authors: R N Faradji; K Monroy; A Riefkohl; L Lozano; L Gorn; T Froud; P Cure; D Baidal; G Ponte; S Messinger; J Mastrototaro; C Ricordi; R Alejandro Journal: Transplant Proc Date: 2006-12 Impact factor: 1.066